ArticleAnnals of nuclear medicine2024
A prospective study of
Article in Annals of nuclear medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- [European journal of nuclear medicine and molecular imaging · 2025Trial
- Interpretive consistency of a qualitativeEuropean journal of nuclear medicine and molecular imaging · 2026Article
- PSMA expression in hepatic colorectal cancer metastasis.Journal of pathology and translational medicine · 2026Article
- Short-chain fatty acids from gut microbiota restore Th17/Treg balance in rheumatoid arthritis: Mechanisms and therapeutic potential.Journal of translational autoimmunity · 2025Review
- Prostate-specific membrane antigen-targeting radiopharmaceuticals: a new frontier in hepatic malignancies.Frontiers in oncology · 2025Review
- Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential?Neuro-oncology · 2024Review
- Review
- The wings of progress: technological and radiopharmaceutical innovations in nuclear medicine.European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePSMA expression is seen in many solid tumours in addition to prostate cancer and several studies and case reports have shown PSMA expression and
methodsPatients with radiologically and/or histopathologically confirmed HCC were included and all had undergone serum alpha-fetoprotein (S.AFP) assessment as well as CE-CT/MRI prior to PSMA PET/CT. Acquired whole-body PET/CTs were analysed both visually and quantitatively by two experienced nuclear medicine physicians.
resultsForty-one (41) patients (36 male; 5 female) with known HCC and a mean age of 53.9 ± 10.9 years underwent
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.